PRESS RELEASE – FOR IMMEDIATE RELEASE




Sales of €2.5 million in the first half of 2025 and cash position
of €2.1 million
▪ Sequencing activities at Évry down 31%

▪ Decrease in activities on the P2M microbiology platform operated on the Institut Pasteur
site

▪ Free cash position of €2.1m at June 30, 2025, after a consumption of €0.9m in the first half.
The cash situation at this rate of consumption may not allow the company to continue its
activities without new financing beyond the first quarter of 2026


EVRY, FRANCE, JULY 2, 7:30AM CEST - IntegraGen (FR0010908723 – ALINT – Eligible PEA PME), an
OncoDNA company specializing in the genomics of cancer and rare genetic diseases, which performs
interpretable genomic analyses for academic and private laboratories, announces today its unaudited
sales for the first half of 2024.

Sales for the first half came to €2,540K, down 34% compared with the first half of 2024 on a like-for-
like basis (excluding revenues from the SeqOIA platform), contrary to expectations of weak growth,
comparable to that of 2024, as announced by the Company in its press release dated April 29, 2025,
on its results for the 2024 financial year.

This decline is the result of reduced activity of over 40% on the Institut Pasteur's Mutualized
Microbiology platform, linked to the drop in epidemiological sequencing, as well as to the decline in
projects carried out on the Evry genomics platform, down by around 31%.
This decline is the result of delays in the start-up of two major projects, the first samples of which were
received by the company in May, as well as a general slowdown in research projects for academic and
hospital customers. The company believes that the second half of the year, with the acceleration of
major projects (notably UMBRELLA) and improved funding conditions for public research, should
enable the situation to improve from the third quarter onwards.

As of June 30th, available cash, including the remainder on the loan granted to the parent company
OncoDNA and repaid over the course of 2025, stood at €2.1m. The company used up €0.9m of cash in
the first half of 2025, and at this rate may not have enough cash to ensure its financing for the next 12
months.

In this context, the company is exploring all strategic options to improve its situation and expects to
reduce cash consumption in the second half of the year through the reduction of operating costs, the
launch of services for several existing customers, external sources of financing, a resumption of


1/2
customer research projects, as well as the expected upturn in customers' research budgets. Given the
high level of uncertainty surrounding public research funding, the Company is not maintaining its
revenue growth forecasts for 2025.

Bernard Courtieu, Chief Executive Officer of IntegraGen, comments: "The first half of the year has
been extremely difficult, with both a sharp drop in academic and hospital research projects, linked to a
reduction in public research financing, as well as a reduction in the budgets of several biotech
companies in a sector affected by the general economic climate.
Despite several successes such as the UMBRELLA project, whose operational launch was announced
last month, IntegraGen needs to find new sources of funding to be able to ensure the continuity of its
operations."

Investors are invited to carefully read section 4.2 of the 2024 Management Report on “Principal risks
and uncertainties facing the Company”.

Financial results for the first half of 2025 will be published in October.


ABOUT INTEGRAGEN

IntegraGen is an OncoDNA group company specializing in the genomics of cancer and rare genetic diseases.
Backed by highly competent and qualified teams, IntegraGen is a leading player in DNA sequencing services and
genomic data interpretation software. The company runs one of the largest NGS labs in France and operates for
research institutes of excellence. As part of OncoDNA group, IntegraGen leverages the power of next generation
sequencing with the mission of delivering the promise of precision medicine to patients. IntegraGen has about
40 employees and generated €8.5 million of turnover in 2024. Based in France, IntegraGen is part of the Belgian
OncoDNA group present in Spain, UK, Germany and works with an international network of 35 distributors. The
Group also provides biomarker testing and clinical interpretation tools to guide treatment and monitoring of late
stage solid tumors and accelerate the development of new cancer drugs.

IntegraGen is listed on Euronext Growth in Paris (ISIN: FR0010908723 – Mnemo: ALINT – Eligible PEA- PME).




CONTACTS

INTEGRAGEN NEWCAP
Bernard COURTIEU Relations Investisseurs
Directeur Général Louis-Victor DELOUVRIER
integragen@newcap.eu
Virginie De Coster Tél. : +33 (0)1 44 71 98 53
Directeur Administratif et Financier
contact@integragen.com
Tél. : +33 (0)1 60 91 09 00




2/2